ATE293633T1 - Hypoxie-regulierte gene - Google Patents

Hypoxie-regulierte gene

Info

Publication number
ATE293633T1
ATE293633T1 AT98943278T AT98943278T ATE293633T1 AT E293633 T1 ATE293633 T1 AT E293633T1 AT 98943278 T AT98943278 T AT 98943278T AT 98943278 T AT98943278 T AT 98943278T AT E293633 T1 ATE293633 T1 AT E293633T1
Authority
AT
Austria
Prior art keywords
seq
present
patient
regulating
gene
Prior art date
Application number
AT98943278T
Other languages
German (de)
English (en)
Inventor
Paz Einat
Rami Skaliter
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Application granted granted Critical
Publication of ATE293633T1 publication Critical patent/ATE293633T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98943278T 1997-08-21 1998-08-21 Hypoxie-regulierte gene ATE293633T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5645397P 1997-08-21 1997-08-21
PCT/US1998/017296 WO1999009049A1 (en) 1997-08-21 1998-08-21 Hypoxia-regulated genes

Publications (1)

Publication Number Publication Date
ATE293633T1 true ATE293633T1 (de) 2005-05-15

Family

ID=22004501

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98943278T ATE293633T1 (de) 1997-08-21 1998-08-21 Hypoxie-regulierte gene

Country Status (8)

Country Link
US (3) US6455674B1 (enExample)
EP (2) EP1015471A1 (enExample)
JP (2) JP4354633B2 (enExample)
AT (1) ATE293633T1 (enExample)
AU (2) AU9110798A (enExample)
DE (1) DE69829857T2 (enExample)
IL (2) IL134298A0 (enExample)
WO (2) WO1999009046A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
WO2001023426A2 (en) * 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
AU2001268466A1 (en) * 2000-06-13 2001-12-24 Agensys, Inc. 55p4h4: gene expressed in various cancers
AU2001290179B2 (en) * 2000-08-07 2007-07-12 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US7105656B2 (en) 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
WO2003070906A2 (en) * 2002-02-19 2003-08-28 The Children's Hospital Of Philadelphia Cellular genes regulated by hiv-1 infection and methods of use thereof
US7405292B2 (en) 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
KR100939274B1 (ko) * 2004-08-16 2010-01-29 쿠아크 파마수티칼스 인코퍼레이티드 알티피801 억제제의 치료적 용도
DK1791568T3 (da) * 2004-08-16 2012-12-10 Quark Pharmaceuticals Inc Terapeutiske anvendelser af hæmmere af rtp801
NL2000439C2 (nl) * 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
WO2008054534A2 (en) * 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc THERAPEUTIC USES OF RTP801L INHIBITORS
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
CA2701845A1 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
CA2880290C (en) 2012-09-12 2020-10-27 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
JP2014069592A (ja) * 2012-09-27 2014-04-21 Mitsubishi Motors Corp 車載機器の遠隔操作システム
US12023781B2 (en) 2018-03-26 2024-07-02 Sintokogio, Ltd. Shot processing apparatus
CN114940975B (zh) * 2022-06-20 2023-07-25 中国人民解放军总医院 一种ted缺失的细胞系及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1182829A (en) 1967-06-12 1970-03-04 Haldor Frederik Axel Topsoe Improvements in or relating to Nickel Catalysts.
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3838153A (en) 1972-05-16 1974-09-24 Pfizer 6-(alpha-(guanylureidoalkanoylamino)aracylamino)penicillanic acids
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3850572A (en) 1974-03-08 1974-11-26 E Andrus Gravity flow discrete article gas flow isolated thermal treatment device and method
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
ATE132266T1 (de) 1987-05-01 1996-01-15 Stratagene Inc Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5387742A (en) 1990-06-15 1995-02-07 Scios Nova Inc. Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
US5288846A (en) 1990-10-19 1994-02-22 The General Hospital Corporation Cell specific gene regulators
NO176546C (no) 1991-07-09 1995-04-26 Soda Galvano As Anordning for sammenföyning av delkomponenter i möbler
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
WO1994023049A2 (en) 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
US5721265A (en) * 1994-08-05 1998-02-24 Sri International Fluorinated 2-nitroimidazole analogs for detecting hypoxic tumor cells
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Also Published As

Publication number Publication date
WO1999009049A1 (en) 1999-02-25
DE69829857D1 (de) 2005-05-25
IL134298A0 (en) 2001-04-30
US6455674B1 (en) 2002-09-24
US6555667B1 (en) 2003-04-29
US6740738B2 (en) 2004-05-25
JP2009261396A (ja) 2009-11-12
EP1009753B1 (en) 2005-04-20
AU9110798A (en) 1999-03-08
JP2002505841A (ja) 2002-02-26
WO1999009046A1 (en) 1999-02-25
US20030124116A1 (en) 2003-07-03
EP1009753A1 (en) 2000-06-21
EP1009753A4 (en) 2003-01-29
AU9028298A (en) 1999-03-08
EP1015471A1 (en) 2000-07-05
JP4354633B2 (ja) 2009-10-28
DE69829857T2 (de) 2006-02-02
IL188791A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
IL188791A0 (en) Hypoxia-regulating genes
Baxendale et al. Comparative sequence analysis of the human and pufferfish Huntington's disease genes
Olschwang et al. Germ-line mutations in the first 14 exons of the adenomatous polyposis coli (APC) gene
Molven et al. Genomic structure and restricted neural expression of the zebrafish wnt‐1 (int‐1) gene.
Ridinger et al. Clustered organization of S100 genes in human and mouse
Canfield et al. Cloning of the H, K-ATPase beta subunit. Tissue-specific expression, chromosomal assignment, and relationship to Na, K-ATPase beta subunits.
Kroemer et al. Structure and expression of a chicken MHC class I gene
CA2160937A1 (en) Survival motor neuron (smn) gene: a gene for spinal muscular atrophy
JP2854062B2 (ja) ヒトアンギオテンシン変換酵素（ｅｃａ）をコードする核酸、及び特に動脈性高血圧のイン・ビトロ診断のための該核酸の適用
Flemetakis et al. Lotus japonicus gene Ljsbp is highly conserved among plants and animals and encodes a homologue to the mammalian selenium-binding proteins
Peruzzi et al. Identification and chromosomal localisation by fluorescence in situ hybridisation of human gene of phosphoinositide-specific phospholipase C β1
Rae et al. TTYH2, a human homologue of the Drosophila melanogaster gene tweety, is located on 17q24 and upregulated in renal cell carcinoma
EA027258B1 (ru) Способ прогнозирования стиля передвижения у лошади и применение указанного способа для отбора лошади для разведения
Hovemann et al. Heat-shock locus 93D of Drosophila melanogaster: An RNA with limited coding capacity accumulates precursor transcripts after heat shock
Glesne et al. Chromosomal localization and structure of the human type II IMP dehydrogenase gene (IMPDH2)
Ma et al. Molecular characterization of the TCP11 gene which is the human homologue of the mouse gene encoding the receptor of fertilization promoting peptide
Lin et al. Variation in primary sequence and tandem repeat copy number among i-antigens of Ichthyophthirius multifiliis
US5869318A (en) Gene sequence of the Down syndrome critical region of human chromosome 21, identified by a new "Alu-splicing PCR" technique, coding for a proline-rich protein (DSCR1) highly expressed in foetal brain and in heart and method for characterizing it
US5516655A (en) Multiple drug resistance gene of Aureobasidium pullulans
Podgorski et al. Isolation of a cDNA encoding a portion of the cyclic nucleotide phosphodiesterase of Dictyostelium discoideum
KR100319395B1 (ko) 애기장대의 생체시계 및 개화시기 조절 유전자 자이겐티아
McCallion et al. Splicing pattern, transcript start distribution, and DNA sequence of the mouse gene (Mobp) encoding myelin-associated oligodendrocytic basic protein
KR960705934A (ko) 엔도텔린 전환 효소(Endothelin Converting Enzyme)
CN103981189A (zh) 奶牛结核病候选基因card15基因及功能突变检测方法
Middlebrook Molecular Cloning of Snake Toxins and Other Venom Components

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1009753

Country of ref document: EP

EEFA Change of the company name